Baseline characteristics of patients enrolled within the a single arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects trial
| N (full set analysis) | 26 |
| Age, mean (SD) | 78 (±8) years |
| Length of time since diagnosis of exudative AMD, mean (SD) | 14 months (±11 months) |
| Time since last injection prior to study enrolment, mean (SD) | 50 days (±24 days) range: 21–91 days |
| Previous treatment, % (n) | Bevacizumab: 26.9 (7) ranibizumab: 65.4 (17) both: 7.1 (2) |
| Average number of treatments prior to study entry, mean (SD) | 9.62 (±6.58) Range: 3–23 injections |
| E-ETDRS BCVA letter score, mean (SD), Snellen equivalent, mean | 56.42 (±17.04) range: 24–80 20/80 range: 20/25–20/320 |
| Central subfield thickness (µm), mean (SD) | 304.08 (±75.44) range: 210–505 |
AMD, age-related macular degeneration; BCVA, best-corrected visual acuity.